DHA Supplementation in Patients With STGD3
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00420602 |
Recruitment Status :
Completed
First Posted : January 11, 2007
Last Update Posted : May 9, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dominantly Inherited Stargardt's Disease (STGD3) | Dietary Supplement: Over the counter DHA/EPA dietary supplementation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 11 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3 |
Actual Study Start Date : | September 21, 2007 |
Actual Primary Completion Date : | December 27, 2017 |
Actual Study Completion Date : | December 27, 2017 |

Arm | Intervention/treatment |
---|---|
Single Arm, Open Label
Single Arm, Open Label
|
Dietary Supplement: Over the counter DHA/EPA dietary supplementation
1000 mg/day DHA/EPA |
- ERG [ Time Frame: 1 year ]
- Visual acuity [ Time Frame: 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 105 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All Moran Eye Center patients with STGD3
Exclusion Criteria:
- All others

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00420602
United States, Utah | |
Moran Eye Center, University of Utah | |
Salt Lake City, Utah, United States, 84132 |
Principal Investigator: | Paul S. Bernstein, MD Ph.D. | University of Utah |
Responsible Party: | Paul S. Bernstein, Professor of Ophthalmology, University of Utah |
ClinicalTrials.gov Identifier: | NCT00420602 |
Other Study ID Numbers: |
IRB 19676 |
First Posted: | January 11, 2007 Key Record Dates |
Last Update Posted: | May 9, 2018 |
Last Verified: | May 2018 |
Stargardt Disease Eye Diseases, Hereditary Eye Diseases Macular Degeneration |
Retinal Degeneration Retinal Diseases Genetic Diseases, Inborn |